张吉泉，理学博士，教授，博士生/硕士生导师，国家自然科学基金通讯评审专家。2015年毕业于中山大学药学院，目前担任贵州省化学合成药物研发利用工程技术研究中心副主任，入选了贵州省优秀青年科技人才及贵州医科大学青年领军人才计划。近五年主持国家自然科学基金（3项）、贵州省自然科学基金重点项目、贵州省科技支撑计划及贵阳市创新团队等项目10余项；先后在国际期刊Advanced Healthcare Materials, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Journal of Organic Chemistry, Bioorganic Chemistry等上发表SCI论文50余篇，并担任药物化学专业期刊Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry及Bioorganic Chemistry等审稿人；获授权发明专利10余项；曾获贵州省医学科技奖二等奖（第一完成人）及贵州省自然科学奖二等奖（第三完成人）各1项；指导研究生多次获得贵州医科大学优秀毕业论文。
ORCID: https://orcid.org/0000-0002-8034-7551.
研究方向：靶向抗肿瘤药物研究
邮箱：zjqgmc@163.com
通讯地址：贵州省贵安新区安康大道6号贵州医科大学
近年主持的代表性科研项目：
(1) 国家自然科学基金地区基金项目，22267003，基于mTOR/HDAC双重抑制的抗三阴乳腺癌药物分子的设计、合成及生物活性评价，2023/01-2026/12，33.0万。
(2) 国家自然科学基金地区基金项目，82060625，基于获得性耐药的EGFR/PI3Kα双靶点抑制剂的设计、合成及生物活性评价，2021/01-2024/12，35.0万。
(3) 国家自然科学基金青年科学基金项目，81703356，基于嘧啶与三嗪母核的PI3Kα/mTOR双靶点抑制剂的设计、合成及生物活性研究，2018/01-2020/12，20.1万。
(4) 贵州省自然科学基金重点项目，黔科合基础[2020]1Z073，基于获得性耐药的嘧啶类EGFR/PI3Kα双靶点抑制剂的设计、合成及抗肿瘤活性研究，2020/01-2023/12，30万。
(5) 贵州省优秀青年科技人才计划，黔科合平台人才-YQK[2023]030，2023/05-2026/04，20万。
(6) 贵州医科大学优秀青年人才计划，(2022)102, 靶向抗肿瘤药物研究，2022/07-2027/07，200万。
代表性研究论文：
(1) Sun, Q.; Chu, Y.; Zhang, N.; Chen, R.; Wang, L.; Wu, J.; Dong, Y.; Li, H.; Wang, L.*; Tang, L.*; Zhan, C.*; Zhang, J.-Q*. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer. J. Med. Chem., 2024, 67, 7330-7358. (中科院1区, TOP1)
(2) Zhang, J.-Q.; Luo, Y.-J.; Xiong, Y.-S.; Yu, Y.; Tu, Z.-C.; Long, Z.-J.; Lai, X.-J.; Chen, H.-X.; Luo, Y.; Weng, J.; Lu, G*. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. J. Med. Chem. 2016, 59, 7268-7274. (中科院1区, TOP1)
(3) Li, Y.; Han, Q.; Sun, Q.; Wang, X.; Ran, Y.; Ma, Y.; Lu, J.; Jin, Z.; Huang, J.; Wang, Y.; Wang, J.; Chai, Y.*; Li, H.*; Zhang, J,-Q*. Discovery of highly potent mTOR inhibitors aimed at suppressing the progression of acute myeloid leukemia. Bioorg. Chem. 2025, 157, 108287. (中科院2区, TOP)
(4) Wang, T.; Wang, Y.; Lu, J.; Chen, J.; Wang, L.; Ouyang, Z.; Ouyang, W.; Hu, C.; Weng, J.; Zhang, J.-Q*. Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC. Bioorg. Chem. 2024, 151, 107714. (中科院2区, TOP)
(5) Pang, Y.; Chen, Y.; Lin, M.; Zhang, Y.; Zhang, J.*; Wang, L*. MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations. J. Chem. Inf. and Model., 2024, 64, 3689-3705. (中科院2区, TOP)
(6) Ban, Y.; Chu, Y.; Pan, F.; Guo, Z.; Yang, Y.; Wei, X.; Li, G.; Qian, J.; Zhan, C.*; Zhang, J.*; Tang, L*. Lipid-Based Nanocarriers Enabled Oral Delivery of Oleanolic Acid Derivative DKS26 for Diabetes Management. Adv. Healthcare Mater. 2023, 12, 2300639. (中科院1区)
(7) Zheng, X.-M.; Chen, Y.-S.; Ban, Y.-J.; Wang, Y.-J.; Dong, Y.-X.; Lei, L.; Guo, B.; Wang, J.-T.; Tang, L.*; Li, H.-L.*; Zhang, J.-Q*. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs. Eur. J. Med. Chem. 2023, 260, 115754. (中科院1区, TOP)
(8) Zhang, N.-N.; Ban, Y.-J.; Wang, Y.-J.; He, S.-Y.; Qi, P.-P.; Bi, T.; Ma, Y.-F.; Dong, Y.-X.; Guo, B.; Weng, J.; Li, H.-L.; Tang, L.; Zhang, J.-Q*. Virtual screening of novel mTOR inhibitors for the potential treatment of human colorectal cancer. Bioorg. Chem. 2023, 140, 106781. (中科院1区, TOP)
(9) Zhao, S.-S.; Wang, Y.-j.; Tang, L.; Guo, B.; Wang, L.; Zhang, J.-Q.*; Yang, S.-G*. Identifying novel selective PPO inhibitors through structure-based virtual screening and bio-evaluation. RSC Adv. 2023, 13, 10873-10883.
(10) Wu, C.-F.; Wang, Q.-C.; Chen, R.; Zhou, H.-L.; Wu, T.-T.; Du, Y.; Zhang, N.-N.; Zhang, H.-M.; Fan, Z.-Y.; Wang, L.-L.; Hu, C.-J.; Sang, Z.-P.; Li, H.-L.; Wang, L.*; Tang, L.*; Zhang, J.-Q*. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer. Eur. J. Med. Chem. 2022, 229, 114055. (中科院1区, TOP)
(11) Ai, D.; Wu, J.; Cai, H.; Zhao, D.; Chen, Y.; Wei, J.; Xu, J.; Zhang, J.*; Wang, L*. A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors. Front. Pharmacol. 2022, 13, 971369.
(12) Cheng, F.; Bai, X.; Sun, Q.-W.; Zhu, G.-F.; Dong, Y.-X.; Yang, Y.-Y.; Gao, X.-L.; Guo, B.; Tang, L.*; Zhang, J.-Q*. Cobalt-promoted synthesis of sulfurated oxindoles via radical annulation of N-arylacrylamides with disulfides. Org. Biomol. Chem. 2022, 20, 6423-6431.
(13) Zhang, N.-N.; Bai, X.; Zhao, S.-S.; Zheng, X.-M.; Tang, L.; Yang, S.-G.*; Zhang, J.-Q*. Computational study reveals substituted benzimidazole derivatives′ binding selectivity to PI3Kδ and PI3Kγ. J. Mol. Model. 2022, 28, 123.
(14) He, S.; Zhao, D.; Ling, Y.; Cai, H.; Cai, Y.; Zhang, J.*; Wang, L*. Machine learning enables accurate and rapid prediction of active molecules against breast cancer cells. Front. Pharmacol. 2021, 12, 796534.
(15) Wang, L.-L.; Du, Y.; Li, S.-M.; Cheng, F.; Zhang, N.-N.; Chen, R.; Cui, X.; Yang, S.-G.; Fan, L.-L.; Wang, J.-T.; Guo, B.; Wu, H.-S.; Zhang, J.-Q.*; Tang, L*. Design, synthesis and evaluation of tetrahydrocarbazole derivatives as potential hypoglycemic agents. Bioorg. Chem. 2021, 115, 105172. (中科院1区, TOP)
(16) Cheng, F.; Wang, L.-L.; Mao, Y.-H.; Dong, Y.-X.; Liu, B.; Zhu, G.-F.; Yang, Y.-Y.; Guo, B.; Tang, L.*; Zhang, J.-Q*. Iron-Catalyzed Radical Annulation of Unsaturated Carboxylic Acids with Disulfides for the Synthesis of γ-Lactones. J. Org. Chem. 2021, 86, 8620-8629.
(17) Wang, X.-L.; Bai, X.; Wu, C.-F.; Dong, Y.-X.; Zhang, M.; Fan, L.-L.; Tang, L.*; Yang, Y.-Y.*; Zhang, J.-Q*. Direct C(sp3)-H Sulfonylation and Sulfuration Reactions of Isoquinoline-1,3(2H,4H)-diones under Metal-free Conditions. Asian J. Org. Chem. 2021, 10, 386-391.
(18) Wu, T.-T.; Guo, Q.-Q.; Chen, Z.-L.; Wang, L.-L.; Du, Y.; Chen, R.; Mao, Y.-H.; Yang, S.-G.; Huang, J.; Wang, J.-T.; Wang, L.*; Tang, L.*; Zhang, J.-Q*. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. Eur. J. Med. Chem. 2020, 204, 112637. (中科院1区, TOP)
(19) Zhang, J.-Q.*; Li, S.-M.; Wu, C.-F.; Wang, X.-L.; Wu, T.-T.; Du, Y.; Yang, Y.-Y.; Fan, L.-L.; Dong, Y.-X.; Wang, J.-T.; Tang, L.*. The synthesis of symmetrical 3,3-Disubstituted oxindoles by phosphine-catalyzed γ/γ-addition of oxindoles with allenoates. Catal. Commun. 2020, 138, 105838.
(20) Cao, J.; Chen, Z.-L.; Li, S.-M.; Zhu, G.-F.; Yang, Y.-Y.; Wang, C.; Chen, W.-Z.; Wang, J.-T.; Zhang, J.-Q.*; Tang, L*. Palladium-Catalyzed Regioselective C-2 Arylation of Benzofurans with N'-Acyl Arylhydrazines. Eur. J. Org. Chem. 2018, 2018, 2774-2779.
(21) Zhang, J.-Q.; Li, S.-M.; Ma, X.; Zhong, G.; Chen, R.; Li, X.-S.; Zhu, G.-F.; Zhou, B.; Guo, B.; Wu, H.-S.; Tang, L*. Discovery of tetrahydrocarbazoles with potent hypoglycemic and hypolipemic activities. Eur. J. Med. Chem. 2018, 150, 102-112. (中科院1区, TOP)
(22) Zhang, J.-Q.*; Cao, J.; Li, W.; Li, S.-M.; Li, Y.-K.; Wang, J.-T.; Tang, L. Palladium/copper-catalyzed arylation of alkenes with N'-acyl arylhydrazines. New J. Chem. 2017, 41, 437-441.
代表性专利：
(1) Jian-Cun Zhang, Ying-Jun Zhang, Wei-Hong Zhang, Bing Liu, Ji-Quan Zhang, Jin-Lei Liu, Lu Zhang. Aminoquinazoline derivatives and their salts and methods for use. 2013. 05. 23, WO2013071697A1.
(2) 张吉泉，张娜娜，吴春风，王领，汤磊. 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用. 中国专利, 2024-3-5, ZL202210435526.7.
(3) 张吉泉，武婷婷，王丽丽，汤磊，王领.一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用. 中国专利, 2023-03-31, ZL202010025364.0.
(4) 张吉泉，吴春风，王丽丽，武婷婷，汤磊. 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用. 中国专利, 2022-05-20, ZL202110277722.1.
(5) 张吉泉，李述敏，王兴兰，吴春风，段鲁，汤磊. 一种取代吲哚酮类衍生物的制备方法. 中国专利, 2022-08-02, ZL 201910184247.6.
(6) 张吉泉, 曹俊, 王丽丽, 汤磊, 李述敏. 一种新的五元芳杂环和芳环并五元芳杂环芳基化合成方法. 中国专利, 2021-11-19, ZL 201810000789.9.
(7) 张吉泉, 汤磊, 杜克斯, 陈瑞, 李维, 吴昊姝, 陈瑞. 齐墩果酸衍生物及其药物组合物在药物中的应用. 中国专利, 2019-12-03, ZL201610383933.2.
